JP2014526500A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526500A5 JP2014526500A5 JP2014530370A JP2014530370A JP2014526500A5 JP 2014526500 A5 JP2014526500 A5 JP 2014526500A5 JP 2014530370 A JP2014530370 A JP 2014530370A JP 2014530370 A JP2014530370 A JP 2014530370A JP 2014526500 A5 JP2014526500 A5 JP 2014526500A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- trifluoromethyl
- oxadiazol
- halogen atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 32
- 125000005843 halogen group Chemical group 0.000 claims 31
- 229910052799 carbon Inorganic materials 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 7
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- -1 R 14 Chemical compound 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- HNMSYIKEBOLQKV-UHFFFAOYSA-N 2-[5-[3-amino-5,6-bis(trifluoromethyl)pyrazin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound O1C(C(O)(C)C(F)(F)F)=NN=C1C1=NC(C(F)(F)F)=C(C(F)(F)F)N=C1N HNMSYIKEBOLQKV-UHFFFAOYSA-N 0.000 claims 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 230000036571 hydration Effects 0.000 claims 2
- 238000006703 hydration reaction Methods 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- GESXZHFWDCTRHG-SNVBAGLBSA-N (2r)-2-[5-[3-amino-4-chloro-6-methoxy-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound ClC1=C(C(F)(F)F)C(OC)=NC(C=2OC(=NN=2)[C@@](C)(O)C(F)(F)F)=C1N GESXZHFWDCTRHG-SNVBAGLBSA-N 0.000 claims 1
- HNMSYIKEBOLQKV-MRVPVSSYSA-N (2r)-2-[5-[3-amino-5,6-bis(trifluoromethyl)pyrazin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound O1C([C@](O)(C)C(F)(F)F)=NN=C1C1=NC(C(F)(F)F)=C(C(F)(F)F)N=C1N HNMSYIKEBOLQKV-MRVPVSSYSA-N 0.000 claims 1
- GJICZLZFKWSSBD-SECBINFHSA-N (2r)-2-[5-[3-amino-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound O1C([C@](O)(C)C(F)(F)F)=NN=C1C1=NC=C(C(F)(F)F)C=C1N GJICZLZFKWSSBD-SECBINFHSA-N 0.000 claims 1
- HMXVTLCFBUROJI-SNVBAGLBSA-N (2r)-2-[5-[3-amino-6-methoxy-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound C1=C(C(F)(F)F)C(OC)=NC(C=2OC(=NN=2)[C@@](C)(O)C(F)(F)F)=C1N HMXVTLCFBUROJI-SNVBAGLBSA-N 0.000 claims 1
- GESXZHFWDCTRHG-JTQLQIEISA-N (2s)-2-[5-[3-amino-4-chloro-6-methoxy-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound ClC1=C(C(F)(F)F)C(OC)=NC(C=2OC(=NN=2)[C@](C)(O)C(F)(F)F)=C1N GESXZHFWDCTRHG-JTQLQIEISA-N 0.000 claims 1
- CTRQIOYBLMEECE-LBPRGKRZSA-N (2s)-2-[5-[3-amino-4-ethyl-6-methoxy-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound COC1=C(C(F)(F)F)C(CC)=C(N)C(C=2OC(=NN=2)[C@](C)(O)C(F)(F)F)=N1 CTRQIOYBLMEECE-LBPRGKRZSA-N 0.000 claims 1
- HNMSYIKEBOLQKV-QMMMGPOBSA-N (2s)-2-[5-[3-amino-5,6-bis(trifluoromethyl)pyrazin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound O1C([C@@](O)(C)C(F)(F)F)=NN=C1C1=NC(C(F)(F)F)=C(C(F)(F)F)N=C1N HNMSYIKEBOLQKV-QMMMGPOBSA-N 0.000 claims 1
- GJICZLZFKWSSBD-VIFPVBQESA-N (2s)-2-[5-[3-amino-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound O1C([C@@](O)(C)C(F)(F)F)=NN=C1C1=NC=C(C(F)(F)F)C=C1N GJICZLZFKWSSBD-VIFPVBQESA-N 0.000 claims 1
- AIEPIMYPVPRVOQ-INIZCTEOSA-N (2s)-2-[5-[3-amino-6-methoxy-4-phenyl-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C(C=2C=CC=CC=2)=C(C(F)(F)F)C(OC)=NC=1C1=NN=C([C@](C)(O)C(F)(F)F)O1 AIEPIMYPVPRVOQ-INIZCTEOSA-N 0.000 claims 1
- IPXOIMMPOYXWFR-ZDUSSCGKSA-N (2s)-2-[5-[3-amino-6-methoxy-4-prop-1-en-2-yl-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound CC(=C)C1=C(C(F)(F)F)C(OC)=NC(C=2OC(=NN=2)[C@](C)(O)C(F)(F)F)=C1N IPXOIMMPOYXWFR-ZDUSSCGKSA-N 0.000 claims 1
- FDJPJZNPKVAQDQ-ZDUSSCGKSA-N (2s)-2-[5-[3-amino-6-methoxy-4-propan-2-yl-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound CC(C)C1=C(C(F)(F)F)C(OC)=NC(C=2OC(=NN=2)[C@](C)(O)C(F)(F)F)=C1N FDJPJZNPKVAQDQ-ZDUSSCGKSA-N 0.000 claims 1
- HMXVTLCFBUROJI-JTQLQIEISA-N (2s)-2-[5-[3-amino-6-methoxy-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound C1=C(C(F)(F)F)C(OC)=NC(C=2OC(=NN=2)[C@](C)(O)C(F)(F)F)=C1N HMXVTLCFBUROJI-JTQLQIEISA-N 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- ZCPYJTVACTXCQN-UHFFFAOYSA-N 2-(5-benzyl-1,3,4-oxadiazol-2-yl)-6-bromo-5-(trifluoromethyl)pyridin-3-amine Chemical compound NC1=CC(C(F)(F)F)=C(Br)N=C1C(O1)=NN=C1CC1=CC=CC=C1 ZCPYJTVACTXCQN-UHFFFAOYSA-N 0.000 claims 1
- QOFCKRKVCJKVJW-SNVBAGLBSA-N 2-[5-[(r)-amino(phenyl)methyl]-1,3,4-oxadiazol-2-yl]-6-bromo-5-(trifluoromethyl)pyridin-3-amine Chemical compound O1C([C@H](N)C=2C=CC=CC=2)=NN=C1C1=NC(Br)=C(C(F)(F)F)C=C1N QOFCKRKVCJKVJW-SNVBAGLBSA-N 0.000 claims 1
- GJICZLZFKWSSBD-UHFFFAOYSA-N 2-[5-[3-amino-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound O1C(C(O)(C)C(F)(F)F)=NN=C1C1=NC=C(C(F)(F)F)C=C1N GJICZLZFKWSSBD-UHFFFAOYSA-N 0.000 claims 1
- SLYMSJFTGUGSPB-UHFFFAOYSA-N 2-[5-[3-amino-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-thiadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound S1C(C(O)(C)C(F)(F)F)=NN=C1C1=NC=C(C(F)(F)F)C=C1N SLYMSJFTGUGSPB-UHFFFAOYSA-N 0.000 claims 1
- OBYGNKZCTZZYRW-UHFFFAOYSA-N 2-[5-[3-amino-6-bromo-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound O1C(C(O)(C)C(F)(F)F)=NN=C1C1=NC(Br)=C(C(F)(F)F)C=C1N OBYGNKZCTZZYRW-UHFFFAOYSA-N 0.000 claims 1
- GXAUSGXVGWVBKQ-UHFFFAOYSA-N 2-[5-[3-amino-6-bromo-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]propan-2-ol Chemical compound O1C(C(C)(O)C)=NN=C1C1=NC(Br)=C(C(F)(F)F)C=C1N GXAUSGXVGWVBKQ-UHFFFAOYSA-N 0.000 claims 1
- GILUBKYXXVYQHQ-UHFFFAOYSA-N 2-[5-[3-amino-6-cyclopropyl-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound O1C(C(O)(C)C(F)(F)F)=NN=C1C1=NC(C2CC2)=C(C(F)(F)F)C=C1N GILUBKYXXVYQHQ-UHFFFAOYSA-N 0.000 claims 1
- HMXVTLCFBUROJI-UHFFFAOYSA-N 2-[5-[3-amino-6-methoxy-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound C1=C(C(F)(F)F)C(OC)=NC(C=2OC(=NN=2)C(C)(O)C(F)(F)F)=C1N HMXVTLCFBUROJI-UHFFFAOYSA-N 0.000 claims 1
- WIQHUQHSUZPFOM-UHFFFAOYSA-N 2-[5-[3-amino-6-methyl-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound C1=C(C(F)(F)F)C(C)=NC(C=2OC(=NN=2)C(C)(O)C(F)(F)F)=C1N WIQHUQHSUZPFOM-UHFFFAOYSA-N 0.000 claims 1
- BGYUULQTVSRSJN-UHFFFAOYSA-N 3-(5-benzyl-1,3,4-oxadiazol-2-yl)-5-bromo-6-(trifluoromethyl)pyrazin-2-amine Chemical compound NC1=NC(C(F)(F)F)=C(Br)N=C1C(O1)=NN=C1CC1=CC=CC=C1 BGYUULQTVSRSJN-UHFFFAOYSA-N 0.000 claims 1
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 1
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- AVTAXIOQVRBSRX-UHFFFAOYSA-N [5-[3-amino-6-bromo-5-(trifluoromethyl)pyrazin-2-yl]-1,3,4-oxadiazol-2-yl]-phenylmethanone Chemical compound NC1=NC(C(F)(F)F)=C(Br)N=C1C1=NN=C(C(=O)C=2C=CC=CC=2)O1 AVTAXIOQVRBSRX-UHFFFAOYSA-N 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535560P | 2011-09-16 | 2011-09-16 | |
| US61/535,560 | 2011-09-16 | ||
| PCT/IB2012/054826 WO2013038386A1 (en) | 2011-09-16 | 2012-09-14 | Heterocyclic compounds for the treatment of cystic fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526500A JP2014526500A (ja) | 2014-10-06 |
| JP2014526500A5 true JP2014526500A5 (enExample) | 2014-12-11 |
| JP5886433B2 JP5886433B2 (ja) | 2016-03-16 |
Family
ID=47143988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530370A Expired - Fee Related JP5886433B2 (ja) | 2011-09-16 | 2012-09-14 | 嚢胞性線維症処置のためのヘテロ環式化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9034879B2 (enExample) |
| EP (1) | EP2755967B1 (enExample) |
| JP (1) | JP5886433B2 (enExample) |
| CN (1) | CN103946221B (enExample) |
| ES (1) | ES2558457T3 (enExample) |
| WO (1) | WO2013038386A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2745977C2 (ru) | 2010-04-22 | 2021-04-05 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| SG10201913575VA (en) | 2014-04-15 | 2020-02-27 | Vertex Pharma | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| CA2952862A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| EP3798214B1 (en) | 2014-10-06 | 2022-09-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2017005663A (es) | 2014-10-31 | 2018-03-01 | Abbvie Sarl | Tetrahidropiranos sustituidos y metodo de uso. |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| US10344023B2 (en) | 2014-12-23 | 2019-07-09 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| US10392378B2 (en) | 2014-12-23 | 2019-08-27 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| CN107922338A (zh) | 2015-06-02 | 2018-04-17 | 艾伯维公司 | 经取代的吡啶及使用方法 |
| US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
| NZ741093A (en) | 2015-10-06 | 2022-12-23 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
| KR20180083323A (ko) | 2015-10-09 | 2018-07-20 | 애브비 에스.에이.알.엘. | N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법 |
| EP3359540A1 (en) | 2015-10-09 | 2018-08-15 | AbbVie S.À.R.L. | Novel compounds for treatment of cystic fibrosis |
| JP2018530557A (ja) | 2015-10-09 | 2018-10-18 | アッヴィ・エス・ア・エール・エル | 置換ピラゾロ［３，４−ｂ］ピリジン−６−カルボン酸およびこの使用 |
| BR112018070747B1 (pt) | 2016-04-07 | 2024-01-09 | Proteostasis Therapeutics, Inc | Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos |
| EP3448842A1 (en) | 2016-04-26 | 2019-03-06 | AbbVie S.À.R.L. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| EP3472156B1 (en) | 2016-06-21 | 2023-06-07 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| CA3041675A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
| AU2017348186A1 (en) | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc | Pyridazine derivatives, compositions and methods for modulating CFTR |
| WO2018081378A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
| MA49235B1 (fr) | 2016-12-09 | 2021-02-26 | Vertex Pharma | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
| PL3555048T3 (pl) | 2016-12-19 | 2021-12-06 | Novartis Ag | Nowe pochodne kwasu pikolinowego i ich zastosowanie jako związki pośrednie |
| EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| MA49061A (fr) | 2017-04-28 | 2021-04-21 | Proteostasis Therapeutics Inc | Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| US20210369749A1 (en) | 2017-10-06 | 2021-12-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CN111757874B (zh) | 2017-12-08 | 2024-03-08 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| WO2019136314A1 (en) | 2018-01-05 | 2019-07-11 | The Curators Of The University Of Missouri | Compounds and methods for treatment of cystic fibrosis |
| EP3752510B1 (en) * | 2018-02-15 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| EP3747882A1 (en) | 2019-06-03 | 2020-12-09 | AbbVie Overseas S.à r.l. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| TW202115014A (zh) | 2019-07-12 | 2021-04-16 | 美商奧佛麥德公司 | 用於治療囊腫纖維化之化合物 |
| KR20220064366A (ko) | 2019-08-14 | 2022-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 조절제의 결정질 형태 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| CA3157798A1 (en) | 2019-11-12 | 2021-05-20 | Zhongli Gao | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity |
| WO2021113806A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
| WO2021113809A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
| CR20230120A (es) * | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CA3188787A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP2023549547A (ja) * | 2020-11-18 | 2023-11-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとして使用するための１，３，４－オキサジアゾール環を含有する大環状化合物 |
| CA3204725A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2022150174A1 (en) | 2021-01-06 | 2022-07-14 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
| WO2023034946A1 (en) | 2021-09-03 | 2023-03-09 | Genzyme Corporation | Indole compounds and uses thereof in the treatement of cystic fibrosis |
| PE20241330A1 (es) | 2021-09-03 | 2024-06-26 | Genzyme Corp | Compuestos de indol y metodos de uso |
| KR20240155228A (ko) * | 2022-02-03 | 2024-10-28 | 버텍스 파마슈티칼스 인코포레이티드 | (6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법 |
| JP2025506382A (ja) * | 2022-02-03 | 2025-03-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症の治療方法 |
| AU2023218262A1 (en) * | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA3253026A1 (en) * | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | TREATMENT METHODS FOR CYSTIC FIBROSIS |
| US20250340568A1 (en) * | 2022-05-16 | 2025-11-06 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
| KR20250091331A (ko) | 2022-09-07 | 2025-06-20 | 시오나 테라퓨틱스 인크. | 거대환식 화합물, 조성물, 및 이의 사용 방법 |
| WO2024054851A1 (en) | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions and methods of using thereof |
| WO2024054845A1 (en) | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocycic compounds, compositions, and methods of using thereof |
| WO2025132358A1 (en) | 2023-12-21 | 2025-06-26 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| WO1993018007A1 (fr) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Nouveau derive de carbostyrile |
| US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| CA2133439C (en) | 1992-04-02 | 2005-07-26 | Siegfried Benjamin Christensen, Iv | Compounds useful for treating allergic and inflammatory diseases |
| WO1993019750A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic or inflammatory diseases |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| WO1999016766A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzodioxole derivatives |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| WO2000000531A1 (en) | 1998-06-30 | 2000-01-06 | The Dow Chemical Company | Polymer polyols and a process for the production thereof |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| TR200103214T2 (tr) | 1999-05-04 | 2002-03-21 | Schering Corporation | CCR5 antagonistleri olarak yararlì piperazin trevleri. |
| EP1175402B1 (en) | 1999-05-04 | 2005-07-20 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CZ302882B6 (cs) | 1999-08-21 | 2012-01-04 | Nycomed Gmbh | Farmaceutický prostredek |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| CN1426401A (zh) | 2000-04-27 | 2003-06-25 | 贝林格尔英格海姆法玛公司 | 新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途 |
| AU2001266100B9 (en) | 2000-06-27 | 2005-10-06 | Laboratorios S.A.L.V.A.T., S.A. | Carbamates derived from arylalkylamines |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| PT1305329E (pt) | 2000-08-05 | 2007-12-24 | Glaxo Group Ltd | Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| NZ526580A (en) | 2000-12-22 | 2005-04-29 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| WO2002053564A2 (en) | 2000-12-28 | 2002-07-11 | Almirall Prodesfarma Ag | Quinuclidine derivatives and their use as m3 antagonists |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| MY137522A (en) | 2001-04-30 | 2009-02-27 | Glaxo Group Ltd | Novel anti-inflammatory androstane derivatives. |
| ES2307751T3 (es) | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
| DK2327767T3 (en) | 2001-06-21 | 2015-07-27 | Basf Enzymes Llc | nitrilases |
| RU2312854C2 (ru) | 2001-09-14 | 2007-12-20 | Глаксо Груп Лимитед | Производные фенэтаноламина для лечения респираторных заболеваний |
| KR20050030169A (ko) | 2001-10-17 | 2005-03-29 | 유씨비 소시에떼아노님 | 퀴누클리딘 유도체, 이의 제조 방법 및 ｍ2 및/또는 ｍ3무스카린 수용체 억제제로서의 이의 용도 |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| MY130622A (en) | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| RS52522B (sr) | 2001-12-20 | 2013-04-30 | Chiesi Farmaceutici S.P.A. | Derivati 1-alkil-1-azoniabiciklo/2.2.2./oktan karbamata i njihova upotreba kao antagonista muskarinskih receptora |
| AU2003202044A1 (en) | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| AU2003201693A1 (en) | 2002-01-21 | 2003-09-02 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| HRP20040887A2 (en) | 2002-03-26 | 2005-04-30 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7268152B2 (en) | 2002-03-26 | 2007-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| ATE496620T1 (de) | 2002-04-11 | 2011-02-15 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
| EP1507754A1 (en) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| AU2003243870B2 (en) | 2002-06-25 | 2008-11-20 | Merck Frosst Canada Ltd | 8-(biaryl) quinoline PDE4 inhibitors |
| WO2004005258A1 (en) | 2002-07-02 | 2004-01-15 | Merck Frosst Canada & Co. | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| AU2003281355A1 (en) | 2002-07-08 | 2004-01-23 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| WO2004018449A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| EP1556369A1 (en) | 2002-08-10 | 2005-07-27 | ALTANA Pharma AG | Pyridazinone-derivatives as pde4 inhibitors |
| CA2494643A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| DE60313472T2 (de) | 2002-08-10 | 2008-01-24 | Nycomed Gmbh | Pyrrolidindion-substituierte piperidin-phthalazone als pde4-inhibitoren |
| US20060113968A1 (en) | 2002-08-17 | 2006-06-01 | Altana Pharma Ag | Novel benzonaphthyridines |
| JP2005537312A (ja) | 2002-08-17 | 2005-12-08 | アルタナ ファルマ アクチエンゲゼルシャフト | 新規のフェナントリジン |
| CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| WO2004018422A1 (en) | 2002-08-23 | 2004-03-04 | Ranbaxy Laboratories Limited | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists |
| JP4587294B2 (ja) | 2002-08-29 | 2010-11-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４インヒビターとしての２−ヒドロキシ−６−フェニルフェナントリジン |
| ATE353217T1 (de) | 2002-08-29 | 2007-02-15 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
| EP1539141B1 (en) | 2002-08-29 | 2010-07-14 | Boehringer Ingelheim Pharmaceuticals Inc. | 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| BR0314304A (pt) | 2002-09-18 | 2005-07-26 | Ono Pharmaceutical Co | Drogas e derivados de triazapiro[5.5]undecano compreendendo o mesmo como o ingrediente ativo |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| EP1542996A4 (en) | 2002-09-20 | 2009-11-18 | Merck & Co Inc | OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| OA12938A (en) | 2002-10-11 | 2006-10-13 | Pfizer | Indole derivatives as beta-2 agonists. |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| US7238725B2 (en) | 2002-10-23 | 2007-07-03 | Glenmark Pharmaceuticals Ltd. | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| EP1556342B1 (en) | 2002-10-28 | 2008-03-26 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| JP4606408B2 (ja) | 2003-01-21 | 2011-01-05 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的グルココルチコイド受容体調節物質としての１７−カルバモイルオキシコルチゾル誘導体 |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| AU2004245174A1 (en) | 2003-06-10 | 2004-12-16 | Ace Biosciences A/S | Extracellular Aspergillus polypeptides |
| CN102015662A (zh) * | 2008-05-13 | 2011-04-13 | 诺瓦提斯公司 | 3,5-二氨基-6-氯-吡嗪-2-甲酸衍生物和它们作为上皮钠通道阻断剂用于治疗气道疾病的用途 |
| MX2011004953A (es) * | 2008-11-10 | 2011-12-14 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| ES2921576T3 (es) * | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| EP2421528A4 (en) * | 2009-04-20 | 2012-10-17 | Inst Oneworld Health | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES |
| WO2010151747A1 (en) * | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimine compounds and methods of making and using same |
| EP2569313A1 (en) * | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
-
2012
- 2012-09-14 ES ES12783308.5T patent/ES2558457T3/es active Active
- 2012-09-14 CN CN201280056105.8A patent/CN103946221B/zh not_active Expired - Fee Related
- 2012-09-14 JP JP2014530370A patent/JP5886433B2/ja not_active Expired - Fee Related
- 2012-09-14 WO PCT/IB2012/054826 patent/WO2013038386A1/en not_active Ceased
- 2012-09-14 EP EP12783308.5A patent/EP2755967B1/en not_active Not-in-force
- 2012-09-14 US US14/343,861 patent/US9034879B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526500A5 (enExample) | ||
| JP2014526501A5 (enExample) | ||
| RU2485131C2 (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства | |
| JP2012515787A5 (enExample) | ||
| JP2014530900A5 (enExample) | ||
| JP2019513776A5 (enExample) | ||
| JP2015512435A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| JP2009507896A5 (enExample) | ||
| JP2011502958A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2005517006A5 (enExample) | ||
| JP2010534647A5 (enExample) | ||
| JP2013529210A5 (enExample) | ||
| JP2014514360A5 (enExample) | ||
| JP2008500992A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2014505107A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2012515788A5 (enExample) | ||
| JP2018515525A5 (enExample) | ||
| RU2011105151A (ru) | Азольные соединения | |
| JP2014532754A5 (enExample) |